eFFECTOR Therapeutics, Inc. announced it has appointed Mayank J. Gandhi, M.D., as chief business officer. Dr. Gandhi will lead eFFECTOR's corporate growth strategy, business development and partnership opportunities Dr. Gandhi has over 15 years of biopharmaceutical industry and capital markets experience, most recently serving as the vice president of corporate development & strategy of Jiya Acquisition Group, a VC-backed biotech special purpose acquisition company, where he helped raise over $100 million for its IPO listing in November of 2020. Prior to joining Jiya, he served as a business development director for Genentech, where he was responsible for identifying, negotiating and closing deal structures across therapeutic modalities and platform technologies.

Prior to that, he held different roles across commercial operations and medical affairs at Genentech and was part of a team that successfully launched Tecentriq in bladder and lung cancer. Earlier in his career, he was an equity research analyst covering biopharma and medical technology companies at Citigroup, Cowen and Avet Capital. Dr. Gandhi received his medical degree from the University of Mumbai, and his M.B.A. with a concentration in healthcare management and finance from Case Western Reserve University.